Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • Rights and Permissions
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • Rights and Permissions
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy

Herbert J. Zeh III, Donna Perry-Lalley, Mark E. Dudley, Steven A. Rosenberg and James C. Yang
J Immunol January 15, 1999, 162 (2) 989-994;
Herbert J. Zeh
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna Perry-Lalley
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark E. Dudley
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Rosenberg
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James C. Yang
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Generation of anti-TRP-2 CTL with high and low peptide concentrations. INF-γ release of primary CTL cultures (day 9) generated with either 10−5 M (A) or 10−9 M (B) TRP-2180–188 peptide in response to 293Kb target cells pulsed with peptide and tumor targets. Both naive and immune animals generated low avidity CTL when 10−5 M of in vitro-stimulating peptide was used. Only immune animals were able to yield Ag-specific CTL when the concentration of in vitro-stimulating peptide was reduced to 10−9 M.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Generation of anti-p15E CTL with high and low peptide concentrations. INF-γ release of primary CTL cultures (day 9) generated with either 10−5 M or 10−9 M p15e604–611 peptide in response to 293Kb cells pulsed peptide and tumor targets. As was true for TRP-2, both naïve and immune animals generated low avidity CTL when 10−5 M of in vitro-stimulating peptide was used A. Only immune animals were able to yield Ag-specific CTL when the concentration of in vitro-stimulating peptide was reduced to 10−9 M (B).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    High concentrations of in vitro-stimulating peptide are detrimental to the generation of high avidity CTL. Splenocytes from B16-immune animals (A) or from animals immune to the p15E-expressing tumor MCA205 (B) were stimulated in vitro with titered concentrations of the appropriate peptide epitope. Primary cultures were tested (day 9) for the ability to release IFN-γ in response to tumor targets or to 293Kb cells pulsed with the appropriate autologous peptide. High concentrations of in vitro-stimulating peptide were detrimental to development of high avidity CTL for both these tumor-associated Ags. Results are representative of at least four independent experiments for each Ag.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Selective expansion of high or low avidity CTL lines. CTL lines were generated by restimulation of primary cultures as described in Materials and Methods. TRP-2-specific CTL lines expanded over four in vitro stimulations with high concentrations of peptide (10−5 M) demonstrated low avidity for peptide-pulsed targets. CTL expanded in low concentrations (10−9 M) of stimulating peptide demonstrated high avidity for the peptide Ag (A). Similarly, high and low avidity CTL lines were able to be generated for the p15E Ag (B).

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Treatment of day 4 B16 pulmonary metastases by high and low avidity CTL lines. A total of 3 × 106 high and low avidity TRP-2-specific CTL were adoptively transferred into C57BL/6 mice bearing day 4 pulmonary metastases as described in Materials and Methods. Fourteen days later mice were sacrificed an the number of pulmonary metastases were enumerated in a coded, blinded fashion. Two-tailed p values were calculated using the Wilcoxon Rank Sum test. In a separate experiment, 7 × 104 high or low avidity p15E-specific CTL were used to treat 4-day established B16 pulmonary metastases (B). For both Ags, only the high avidity CTL effectively reduced the number of pulmonary metastases. Results are representative of two independent experiments for each Ag.

PreviousNext
Back to top

In this issue

The Journal of Immunology: 162 (2)
The Journal of Immunology
Vol. 162, Issue 2
15 Jan 1999
  • Table of Contents
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
Citation Tools
High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy
Herbert J. Zeh, Donna Perry-Lalley, Mark E. Dudley, Steven A. Rosenberg, James C. Yang
The Journal of Immunology January 15, 1999, 162 (2) 989-994;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy
Herbert J. Zeh, Donna Perry-Lalley, Mark E. Dudley, Steven A. Rosenberg, James C. Yang
The Journal of Immunology January 15, 1999, 162 (2) 989-994;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Early Self-Regulatory Mechanisms Control the Magnitude of CD8+ T Cell Responses Against Liver Stages of Murine Malaria
  • Sublethal Hyperoxia Impairs Pulmonary Innate Immunity
  • Dependence of IL-4, IL-13, and Nematode-Induced Alterations in Murine Small Intestinal Smooth Muscle Contractility on Stat6 and Enteric Nerves
Show more Host Defense

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2019 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606